Ulcerative Colitis Market

Ulcerative Colitis Market Size (2022 to 2027)

The global ulcerative colitis market was valued at USD 5.80 billion in 2022. It is further projected to grow at a CAGR of 6.7% and be worth USD 8.03 billion by 2027.

Ulcerative colitis is an inflammatory bowel disease that can cause ulcers in the larger intestine, irritation, and inflammation. The primary cause of the disease is a dysfunctional immune system failing white blood cells; due to ulcerative colitis, the white blood cells start attacking the colon's lining, leading to severe inflammation and ulcers. Ulcerative colitis does not have a complete cure, but the disease can be controlled by taking proper treatments at regular intervals.

MARKET DRIVERS:

Y-O-Y growth in the incidence of ulcerative colitis, commercialization, and the influx of healthcare investments leads to the development of novel treatment procedures that are expected to drive growth in the global ulcerative colitis market.

The availability of advanced treatments for ulcerative colitis due to technological advancements and the increasing patient pool in need of treatment are critical catalyzing factors responsible for the growth of the ulcerative colitis market. Other responsible factors for the market's growth are increasing demand for symptomatic therapeutics, the influx of enhancing drugs into the market, and the increasing adoption of steroids and biologics to treat ulcerative colitis.

The ulcerative colitis market is increasing and is expected to offer lucrative market opportunities due to increasing demand for ulcerative colitis, lack of medication, personalized therapy, and curative therapy for ulcerative colitis. In addition, increasing initiatives on research and developments by public and private organizations in health care are expected to boost the opportunities for stakeholders operating in the ulcerative colitis market.

MARKET RESTRAINTS:

The stringent approval process for biosimilars is the primary factor restraining the growth of the global ulcerative colitis market. Unfavorable rules and policies and Varying conditions in different countries also limit the growth of the ulcerative colitis market. Patent expiration of blockbuster drugs is expected to slow down the growth pace of the ulcerative colitis market during the forecast period. In addition, some of the side effects of the drugs, such as Nausea, Diarrhoea, fever, and headache, is the factor that restrains the market growth.

Impact of COVID-19 on the global ulcerative colitis market:

In early 2021, the COVID-19 outbreak started to spread worldwide, infecting millions of people and prompting large governments worldwide to declare it a public health emergency. The emerging COVID-19 outbreak has negatively impacted many markets. UC is a severe inflammatory disease of the large intestine or colon. This condition affects people of all ages. COVID-19 has been found to have a greater risk of adverse effects in patients with ulcerative colitis than in patients with Crohn's disease. Coronavirus disease (COVID-19) risks and results more in patients with inflammatory bowel disease. Due to this, over the forecast period of 2021 to 2026, the global ulcerative colitis market is expected to grow moderately due to new advances in ulcerative colitis for COVID19 affected people.

REPORT COVERAGE:

This research report on the global ulcerative colitis market has been segmented and sub-segmented into the following categories

Ulcerative Colitis Market - By Product:

• Monoclonal Antibodies
• Biosimilars
• Pharmaceuticals

Based on product, Biosimilars hold the largest market share due to their high production in the last decade due to the patent expiration of branded drugs. Monoclonal antibodies are the fastest-growing segment due to their effectiveness in curing the disease. The pharmaceuticals segment is the next segment that drives the market forward. Increasing innovation in the drug and reducing side effects, and manufacturing personalized drugs drive the pharmaceutical segment forward.

Ulcerative Colitis Market - By Type:

• Proctosigmoiditis
• Ulcerative Proctitis
• Pancolitis
• Left-sided Colitis

Based on type, the Proctosigmoiditis segment is the most common type of ulcerative colitis; hence, it holds a significant market share.

Ulcerative Colitis Market - By Route of Administration:

• Oral
• Injectable

Oral medication has the highest market share due to the increasing preference for oral tablets and syrups over injectable forms. In addition, most doctors prefer this solid oral drug to patients with ulcerative colitis, which drives the segment growth forward.

Ulcerative Colitis Market - By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa

Geographically, the North American region is forecasted to account leading share in the global ulcerative colitis market. The presence of established key players and the increasing patient pool of UC patients is the most significant factor driving regional development. Furthermore, the advanced healthcare system is expected to propel the ulcerative colitis market significantly during the forecast period. Johnson & Johnson Services Inc. announced new results from its Phase Ill UNIFI trial in March 2019, demonstrating that STELARA benefits adults with mild to severe ulcerative colitis. In Canada, 1 in every 150 Canadians is affected with inflammatory bowel disease (IBD), and 100 people per 100,000 suffer from the disease in the United States. All these factors drive the market in the North American region.

Europe is in second place due to the government's supportive policies, which have resulted in the growth of the regional ulcerative colitis sector. The European Medicines Agency's Committee has started recommending the grating treatment of adult patients with moderate to severe ulcerative colitis. More than two million people are suffering from these diseases. In Germany, there are nearly 170,000 ulcerative colitis cases in a year. An increasing incidence of these cases yearly drives the market forward. The German government is providing cost-effective treatment for people suffering from these diseases. In this region, several medications have been approved to treat UC patients. The people who are suffering from this disease also increase the risk of developing colon cancer.

During the analysis period, the regional demand is expected to be significantly fueled by economic growth and improved healthcare services. Focus on developing healthcare facilities and the funding given by numerous governments; the APAC region is expected to be the fastest-growing ulcerative colitis sector. Furthermore, emerging countries such as India and China are expected to contribute significantly to the growth of the regional economy. In the last ten years, there has been an increase in UC patients in China. Nearly 20% of patients are using steroids for this ulcerative colitis disease. Azathioprine is the most recommend drug for this disease. Due to the side effects of this disease, Chinese herbal medicine is widely used to treat ulcerative colitis in China. Chinese herbal medicine helps improve abdominal pain and diarrhea and reduces inflammation in patients with ulcerative colitis. In Japan, the number of ulcerative colitis patients has been increasing gradually. This is due to increasing meat consumption, a high-fiber diet, fatty foods, and dairy products. Due to changing lifestyles, most people are affected by this ulcerative colitis disease. Increasing awareness programs and detecting disease early can cure the disease, which drives the market forward. India is in the second position with the highest number of people suffering from Inflammatory Bowel Disease. India is estimated to have 1.6 million people suffering from Inflammatory Bowel Disease, which drives the market forward in this region. India also educates people with several programs and campaigns for awareness of diseases. The campaign was launched on May 19, 2020, on World IBD Day. Additionally, increased awareness among physicians, improved diagnostic techniques, increasing disease burden of IBD in Asia, changes in dietary patterns, and better hygienic conditions are the factors that drive the market forward.

Due to poor political and economic conditions, the MEA zone is expected to have the smallest ulcerative colitis market share. In addition, a lack of understanding and a poorly developed healthcare system will likely stifle demand growth. However, due to the increase in Ulcerative colitis in the middle east, the market is expected to have a market share in the coming years. In Saudi Arabia, the increasing incidence of ulcerative colitis in children and advanced healthcare in this region drive the market forward. In sub-Saharan Africa, ulcerative colitis has increased in recent years. Diarrhea and rectrices frequently result in the diagnosis of viral diarrhea and even hemorrhoids.

KEY MARKET PARTICIPANTS:

Some of the prominent companies leading the global ulcerative colitis market profiled in this report are Abbott Laboratories, GlaxoSmithKline, Pfizer, Takeda Pharmaceuticals, AbbVie, Johnson and Johnson, Merck, Sanofi, F. Hoffmann-La Roche, Shire Pharmaceuticals. The ulcerative colitis market comprises several Key companies, such as AbbVie Inc., Merck, Johnson and Johnson, and others. These companies have implemented strategic plans to strengthen their market position, such as mergers, new product launches, acquisitions, and partnerships.

RECENT MARKET DEVELOPMENTS:

• In May 2018, Takeda Pharmaceutical Company Limited and Shire PLC announced that Takeda had agreed on a proposed offer to acquire all of Shire's outstanding and future common shares. Based on research and studies conducted in 2019, it is evident that the mitochondrial genes and function are reduced in ulcerative colitis patients. The activity of the chain that transports the electrons is compromised.
• In June 2019, Abbvie Company completed the acquisition of Allergan to expand its product portfolio to offer extensively advanced treatments for patients.
• In 2021, InDex Pharmaceuticals Holding AB (publ) partnered with Parexel Biotech to treat moderate to severe left-sided ulcerative colitis.
• In 2019, Salix Pharmaceuticals started working on treating and preventing gastrointestinal diseases, which Bausch Health Companies Inc owns.